secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001558370-24-011088
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q2 revenue up 15% to $10.4M; core revenue down 9% to $7.6M; SPL revenue jumps 279%
--------------------------------------------------------------------------------

- Total revenue $10.4M (+15% YoY); core business revenue $7.6M (-9% YoY); SPL program-related revenue $2.9M (+279% YoY).
- Net loss narrowed to $9.4M from $10.5M in Q2 2023; EBITDA loss $10.9M vs $12.0M.
- Signed five new SPLs YTD including Legend Biotech (May) and Be Biopharma (Mar); total SPL partners now 28.
- Ended Q2 with $199.8M cash; now expects FY2024 ending cash at least $180M, up from prior $175M guidance.
- Raised FY2024 SPL revenue guidance to ~$6M; core business revenue guidance reaffirmed flat to 5% growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024011088/0001558370-24-011088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024011088/mxct-20240806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer